EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
EMA's CHMP has recommended the approval of CStone's sugemalimab for the first-line treatment of metastatic non-small cell lung cancer.
EMA's CHMP has recommended the approval of CStone's sugemalimab for the first-line treatment of metastatic non-small cell lung cancer.
What's Your Reaction?
